- Home
- INTU vs SNY Comparison
INTU vs SNY Comparison
Compare INTU & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTU
- SNY
- Stock Information
- Founded
- INTU 1983
- SNY 1994
- Country
- INTU United States
- SNY France
- Employees
- INTU N/A
- SNY N/A
- Industry
- INTU Computer Software: Prepackaged Software
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- INTU Technology
- SNY Health Care
- Exchange
- INTU Nasdaq
- SNY Nasdaq
- Market Cap
- INTU 171.6B
- SNY 144.8B
- IPO Year
- INTU 1993
- SNY N/A
- Fundamental
- Price
- INTU $598.92
- SNY $55.82
- Analyst Decision
- INTU Buy
- SNY Buy
- Analyst Count
- INTU 20
- SNY 2
- Target Price
- INTU $721.79
- SNY $62.50
- AVG Volume (30 Days)
- INTU 1.7M
- SNY 3.0M
- Earning Date
- INTU 05-22-2025
- SNY 04-24-2025
- Dividend Yield
- INTU 0.69%
- SNY 3.94%
- EPS Growth
- INTU 9.41
- SNY 2.94
- EPS
- INTU 10.70
- SNY 4.60
- Revenue
- INTU $17,167,000,000.00
- SNY $45,849,466,833.00
- Revenue This Year
- INTU $14.95
- SNY $6.91
- Revenue Next Year
- INTU $12.28
- SNY $6.60
- P/E Ratio
- INTU $55.97
- SNY $23.82
- Revenue Growth
- INTU 13.73
- SNY 7.73
- 52 Week Low
- INTU $553.24
- SNY $45.22
- 52 Week High
- INTU $714.78
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- INTU 48.77
- SNY 47.61
- Support Level
- INTU $605.22
- SNY $53.98
- Resistance Level
- INTU $620.61
- SNY $56.93
- Average True Range (ATR)
- INTU 13.17
- SNY 0.78
- MACD
- INTU 1.20
- SNY -0.56
- Stochastic Oscillator
- INTU 61.53
- SNY 31.19
About INTU Intuit Inc.
Intuit serves small and midsize businesses with accounting software QuickBooks and online marketing platform Mailchimp. The company also operates retail tax filing tool TurboTax, personal finance platform Credit Karma, and a suite of professional tax offerings for accountants. Founded in the mid-1980s, Intuit enjoys a dominant market share for small business accounting and do-it-yourself tax filing in the US.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.